Beta Drugs Ltd (BETA) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 0 | NSE: BETA | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

Beta Drugs Ltd (BETA) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 0 | NSE: BETA | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Beta Drugs

Based on:

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Semi Strong

Beta Drugs stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
109.33
Market Cap:
1,687.2 Cr.
52-wk low:
0
52-wk high:
0

Is Beta Drugs Ltd an attractive stock to invest in?

1. Is Beta Drugs Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Beta Drugs Ltd is a good quality company.

2. Is Beta Drugs Ltd undervalued or overvalued?

The key valuation ratios of Beta Drugs Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Beta Drugs Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Beta Drugs Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Beta Drugs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Beta Drugs Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 21.9%48.9%28.6%18.4%16.9%15.9%26.9%27.9%27.3%13.5%-
Value Creation
Index
0.62.51.10.30.20.10.91.01.00.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 26.441.750.658.165.379.5125158198220220
Sales YoY Gr.-57.9%21.4%14.8%12.5%21.7%57.1%26.5%25.2%11.4%-
Adj EPS 1.87.48.18.876.914.118.621.718.515.3
YoY Gr.-308.8%9.3%8.5%-20.2%-1.3%104.1%32%16.6%-15.1%-
BVPS (₹) 3.59.736.244.755.962.876.795.4114.9127.8127.8
Adj Net
Profit
1.14.67.487.1714.318.821.918.615
Cash Flow from Ops. -0.44.717.17.76.111.618.810.221.218-
Debt/CF from Ops. -22.51.70.511.50.50.40.60.37.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 26.6%27.5%20.8%11.4%
Adj EPS 29.4%21.4%9.4%-15.1%
BVPS49.1%18%18.5%11.2%
Share Price - 69.8% 31.8% -25.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
69.411237.721.714.611.720.221.720.715.212
Op. Profit
Mgn %
11.418.720.418.41819.320.219.81714.3NAN
Net Profit
Mgn %
4.311.114.513.710.88.811.411.911.18.57
Debt to
Equity
3.81.40.20.20.20.10.10.10.11-
Working Cap
Days
65991381802111961491571701870
Cash Conv.
Cycle
22647637366414951460

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 20.82%

Return on Equity has declined versus last 3 years average to 12.00%

Net Profit has been subdued in last 3 years 9.35%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Beta Drugs Ltd.

Standalone Consolidated
TTM EPS (₹) 15.3 42
TTM Sales (₹ Cr.) 220 362
BVPS (₹.) 127.8 195.3
Reserves (₹ Cr.) 119 187
P/BV 13.08 8.56
PE 109.33 39.78
From the Market
52 Week Low / High (₹) 0.00 / 0.00
All Time Low / High (₹) - / -
Market Cap (₹ Cr.) 1,687
Equity (₹ Cr.) 10.1
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Beta Drugs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Beta Drugs - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Beta Drugs

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales264251586579125158198220
Operating Expenses 233441485464100127164189
Manufacturing Costs01678912151722
Material Costs1524273035437183112120
Employee Cost 3412457101115
Other Costs 55687710182432
Operating Profit 37910121525313431
Operating Profit Margin (%) 11.4%17.5%18.7%17.8%18.0%19.3%20.2%19.8%17.0%14.3%
Other Income 0000011126
Interest 1111110115
Depreciation 1122355657
Exceptional Items 000000000-5
Profit Before Tax 157791020252921
Tax 010-0236685
Profit After Tax 14787714192215
PAT Margin (%) 4.3%10.2%13.4%13.3%10.9%8.8%11.4%11.9%11.1%7.0%
Adjusted EPS (₹)1.86.87.58.57.06.914.118.621.715.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 26334156637796116129
Share Capital 1199101010101010
Reserves 15243247546887106119
Minority Interest0000000000
Debt886674544124
Long Term Debt443533544124
Short Term Debt4441410000
Trade Payables4761091320233641
Others Liabilities 134910812142028
Total Liabilities 152350668389115137175321

Fixed Assets

Gross Block9111819424354606590
Accumulated Depreciation2357101520252936
Net Fixed Assets 781312322834353653
CWIP 00115020000
Investments 0002677766
Inventories3236688142227
Trade Receivables4111417212131445049
Cash Equivalents flag 0012348161827142
Others Assets 02610141519213344
Total Assets 152350668389115137175321

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -0517861219102118
PBT 157791020252925
Adjustment 221522430-6-8
Changes in Working Capital -3-3-5-1-4-2-5-15-20
Tax Paid -0000000000
Cash Flow From Investing Activity -2-2-11-16-14-3-13-6-11-21
Capex -2-2-8-15-8-3-10-7-6-24
Net Investments 000-2-5-00-010
Others 00-30-21-31-53
Cash Flow From Financing Activity 3-35-19-41-2-1118
Net Proceeds from Shares 0080900000
Net Proceeds from Borrowing 0-1-13-1-02-10123
Interest Paid -1-1-1-1-1-1-0-1-1-5
Dividend Paid 0000000000
Others 3-1-0-23-3-100-0
Net Cash Flow 0012-914729115

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)69.39103.2234.732114.6311.6420.2321.6620.6712.6
ROCE (%)21.9148.9128.6318.4216.8515.9126.9127.9327.2713.53
Asset Turnover Ratio2.272.171.391.010.880.921.231.261.270.89
PAT to CFO Conversion(x)-01.252.4310.861.711.360.530.951.2
Working Capital Days
Receivable Days3165901001079676878782
Inventory Days29231929353224263341
Payable Days7585889810295859496116

Beta Drugs Ltd Stock News

Beta Drugs Ltd FAQs

The current trading price of Beta Drugs on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Beta Drugs stood at ₹1,687.2.
The latest P/E ratio of Beta Drugs as of 31-Dec-1969 is 109.3.
The latest P/B ratio of Beta Drugs as of 31-Dec-1969 is 13.08.
The 52-week high of Beta Drugs is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Beta Drugs is ₹220.2 ( Cr.) .

About Beta Drugs Ltd

No data to display
You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×